influenza

In his weekly clinical update Dr. Griffin discusses high points of the multi-national monkeypox outbreaks, monkeypox virus genome mutations, possible occupational infection of healthcare workers with monkeypox virus, rates of monkeypox cases by vaccination status, protection of SARS-CoV-2 infection against reinfection, Paxlovid significantly reduces COVID-19 hospitalizations and deaths, and rebound in COVID19 with and without Paxlovid treatment.

In his weekly clinical update Dr. Griffin discusses increased acute respiratory illnesses among children and adolescents, estimates of monkeypox incubation period, generation time, and reproduction number, rapid increase in suspected SARS-CoV-2 reinfections, interim infection prevention and control recommendations for healthcare personnel during COVID-19, SARS-CoV-2 secondary attack rates in vaccinated and unvaccinated household contacts during replacement of delta with omicron variant, breakthrough infection by SARS-CoV-2 delta and omicron variants elicited immune response comparable to mRNA booster vaccination, interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses, further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants, short-course early outpatient Remdesivir prevents severe disease due to COVID-19 in organ transplant recipients during the Omicron BA.2 wave, effectiveness of Molnupiravir in high risk patients, and primary care and a distinct symptom pattern for long COVID.

In his weekly clinical update Dr. Griffin reviews the public health response to poliovirus in New York, impact of mandatory influenza vaccination, monkeypox in a young infant, health care worker exposure to monkeypox virus, monkeypox testing delays, transmission potential of monkeypox virus, TPOXX trial for monkeypox, detection of SARS-CoV-2 subgenomic mRNA, mucosal IgA against SARS-CoV-2, BNT262b2 against Omicron, awareness and use of SARS-CoV-2 antivirals, comparable outcomes for Bebtelovimab and Nirmatrelvir, and COVID-19 and Alzheimer’s disease.

In his weekly clinical update Dr. Griffin discusses detection of a highly divergent type 3 vaccine-derived poliovirus in a child with a severe primary immunodeficiency disorder, severe respiratory illnesses associated with rhinoviruses and/or enteroviruses including EV-D68, effects of vaccination and previous infection on Omicron infections in children, COVID-19-associated hospitalizations among vaccinated and unvaccinated adults 18 years or older in 13 US states, effectiveness of COVID-19 vaccines over time prior to Omicron emergence in Ontario, Canada, nasal IgA wanes 9 months after hospitalization with COVID-19 and is not induced by subsequent vaccination,  resistance of SARS-CoV-2 Omicron subvariant BA.4.6 to antibody neutralization, persistent circulating SARS-CoV-2 spike associated with post-acute COVID-19 sequelae, and impact of COVID-19 vaccination on the risk of developing long-covid and on existing long-covid symptoms.